Statin Therapy and Risk of Developing Type 2 Diabetes: A Meta-Analysis
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Although statin therapy reduces cardiovascular risk, its relationship with the development of diabetes is controversial. The first study (West of Scotland Coronary Prevention Study [WOSCOPS]) that evaluated this association reported a small protective effect but used nonstandardized criteria for diabetes diagnosis. However, results from subsequent hypothesis-testing trials have been inconsistent. The aim of this meta-analysis is to evaluate the possible effect of statin therapy on incident diabetes. RESEARCH DESIGN AND METHODS: A systematic literature search for randomized statin trials that reported data on diabetes through February 2009 was conducted using specific search terms. In addition to the hypothesis-generating data from WOSCOPS, hypothesis-testing data were available from the Heart Protection Study (HPS), the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study, the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT), the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER), and the Controlled Rosuvastatin Multinational Study in Heart Failure (CORONA), together including 57,593 patients with mean follow-up of 3.9 years during which 2,082 incident diabetes cases accrued. Weighted averages were reported as risk ratios (RRs) with 95% CIs using a random-effects model. Statistical heterogeneity scores were assessed with the Q and I2 statistic. RESULTS: In the meta-analysis of the hypothesis-testing trials, we observed a small increase in diabetes risk (RR 1.13 [95% CI 1.03–1.23]) with no evidence of heterogeneity across trials. However, this estimate was attenuated and no longer significant when the hypothesis-generating trial WOSCOPS was included (1.06 [0.93–1.25]) and also resulted in significant heterogeneity (Q 11.8 [5 d.f.], P = 0.03, I2 = 57.7%). CONCLUSIONS: Although statin therapy greatly lowers vascular risk, including among those with and at risk for diabetes, the relationship of statin therapy to incident diabetes remains uncertain. Future statin trials should be designed to formally address this issue.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Several studies have reported a modestly increased risk of incident type 2 diabetes with statin use (162,163), which may be limited to those with diabetes risk factors.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [162]
The cited source says what the claim attributes to it.
In the citing paper
“Several studies have reported a modestly increased risk of incident type 2 diabetes with statin use (156,157), which may be limited to those with diabetes risk factors and/or impaired glucose tolerance.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [156]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In primary prevention, however, among individuals with no previous cardiovascular events, its net benefit is more controversial (156,168).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [156]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Aspirin has been shown to be effective in reducing cardiovascular morbidity and mortality in high-risk individuals with previous MI or stroke (secondary prevention) and is strongly recommended.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [156]
Experimental — accuracy not yet measuredIn the citing paper
“In primary prevention, however, among patients with no previous cardiovascular events, its net bene fi t is more controversial (129,140).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [129]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139 · cited 1×
“To assess heterogeneity across studies, we used the Cochran Q statistic based on the pooled RR by Mantel-Haenszel and measured inconsistency (I(2); the percentage of total variance across studies attributable to heterogeneity rather than chance) of treatment effects across trials (9).”
MethodMeta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552 · cited 1×
“The summary RR and its 95% CI were estimated using the DerSimonian and Laird method for random effects (8).”
MethodAssessing the quality of reports of randomized clinical trials: Is blinding necessary?
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00134-4 · Cited by 17,582
Operating characteristics of a rank correlation test for publication bias
Begg, C. B., & Mazumdar, M. (1994) · Biometrics · doi:10.2307/2533446 · Cited by 16,955
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674 · cited 1×
“Subsequent statin trials did not confirm this protective effect, and in the recent JUPITER a small but significant increase in physician-reported diabetes was reported among statin users compared with those taking placebo, although in the absence of any effect on glucose levels (6).”
ResultSelf-citationSever, P. S., Dahlöf, B., Poulter, N. R., Wedel, H., Beevers, G., Caulfield, M., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12948-0 · Cited by 3,782
Rosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2009) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000344393.60303.0a · Cited by 3,641
Self-citation(2003) · The Lancet · doi:10.1016/s0140-6736(03)13636-7 · Cited by 2,876 · cited 1×
“A few studies have suggested that statin use may result in an increase in A1C levels (2,17), although these effects have been quite small.”
BackgroundRosuvastatin in older patients with systolic heart failure
Kjekshus, J., Apetrei, E., Barrios, V., Böhm, M., Cleland, J. G. F., Cornel, J. H., Dunselman, P., Fonseca, C., Goudev, A., Grande, P., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706201 · Cited by 1,487
Freeman, D. J., Norrie, J., Sattar, N., Neely, R. D. G., Cobbe, S. M., Ford, I., Isles, C., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., et al. (2001) · Circulation · doi:10.1161/01.cir.103.3.357 · Cited by 844 · cited 1×
“(1) reported an inverse association between pravastatin use and diabetes incidence in the WOSCOPS (RR 0.”
Background
Research works printed but not linked: 1
- Sabatine, 2004, High-dose atorvastatin asssociated with worse glycemic control: A PROVE-IT TIMI 22 substudy (Abstract), Circulation, 110, S834
Cited by
Standards of medical care in diabetes—2014
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s014 · Cited by 4,572
Standards of medical care in diabetes—2013
American Diabetes Association (2013) · Diabetes Care · doi:10.2337/dc13-s011 · Cited by 4,369
Statins for the primary prevention of cardiovascular disease
Taylor, F., Huffman, M. D., Macedo, A. F., Moore, T. H., Burke, M., Davey Smith, G., Ward, K., Ebrahim, S., & Gay, H. C. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004816.pub5 · Cited by 1,934
The Role of Inflammation in Diabetes: Current Concepts and Future Perspectives
Tsalamandris, S., Antonopoulos, A. S., Oikonomou, E., Papamikroulis, G.-A., Vogiatzi, G., Papaioannou, S., Deftereos, S., & Tousoulis, D. (2019) · European Cardiology Review · doi:10.15420/ecr.2018.33.1 · Cited by 1,381
Low Wang, C. C., Hess, C. N., Hiatt, W. R., & Goldfine, A. B. (2016) · Circulation · doi:10.1161/circulationaha.116.022194 · Cited by 1,155
10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s010 · Cited by 869
“Diabetes Risk With Statin Use Several studies have reported a modestly increased risk of incident diabetes with statin use (126,127), which may be limited to those with diabetes risk fac-”
BackgroundRidker, P. M., Pradhan, A., MacFadyen, J. G., Libby, P., & Glynn, R. J. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61190-8 · Cited by 816
Self-citationKinoshita, M., Yokote, K., Arai, H., Iida, M., Ishigaki, Y., Ishibashi, S., Umemoto, S., Egusa, G., Ohmura, H., Okamura, T., et al. (2018) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.gl2017 · Cited by 813
Swerdlow, D. I., Preiss, D., Kuchenbaecker, K. B., Holmes, M. V., Engmann, J. E. L., Shah, T., Sofat, R., Stender, S., Johnson, P. C. D., Scott, R. A., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61183-1 · Cited by 680
Self-citationChou, R., Dana, T., Blazina, I., Daeges, M., & Jeanne, T. L. (2016) · JAMA · doi:10.1001/jama.2015.15629 · Cited by 568
10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s010 · Cited by 495
“Diabetes Risk With Statin Use Several studies have reported amodestly increased risk of incident diabetes with statin use (116,117), which may be limited to those with diabetes risk factors.”
Background10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s010 · Cited by 487
10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Das, S. R., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s010 · Cited by 486
9. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2018
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dc18-s009 · Cited by 485
10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s010 · Cited by 471
“statin use (106,107), which may be limited to those with diabetes risk factors.”
Background10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Das, S. R., Hilliard, M. E., Isaacs, D., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s010 · Cited by 465
Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative
Culver, A. L. (2012) · Archives of Internal Medicine · doi:10.1001/archinternmed.2011.625 · Cited by 444
10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Das, S. R., Ekhlaspour, L., Hilliard, M. E., Johnson, E. L., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s010 · Cited by 438
Risk of incident diabetes among patients treated with statins: population based study
Carter, A. A., Gomes, T., Camacho, X., Juurlink, D. N., Shah, B. R., & Mamdani, M. M. (2013) · BMJ · doi:10.1136/bmj.f2610 · Cited by 404
Banach, M., Rizzo, M., Toth, P. P., Farnier, M., Davidson, M. H., Al-Rasadi, K., Aronow, W. S., Athyros, V., Djuric, D. M., Ezhov, M. V., et al. (2015) · Archives of Medical Science · doi:10.5114/aoms.2015.49807 · Cited by 378
“The next meta-analysis reported an even higher – 13% increase in the risk of NOD [37].”
BackgroundInfluentialMills, E. J., WU, P., Chong, G., Ghement, I., Singh, S., Akl, E. A., Eyawo, O., Guyatt, G., Berwanger, O., & Briel, M. (2011) · QJM · doi:10.1093/qjmed/hcq165 · Cited by 338
8. Cardiovascular Disease and Risk Management
American Diabetes Association (2016) · Diabetes Care · doi:10.2337/dc16-s011 · Cited by 329
“Diabetes With Statin Use Several studies have reported an increased risk of incident diabetes with statin use (62,63), which may be limited to those with diabetes risk factors.”
BackgroundCederberg, H., Stančáková, A., Yaluri, N., Modi, S., Kuusisto, J., & Laakso, M. (2015) · Diabetologia · doi:10.1007/s00125-015-3528-5 · Cited by 316
“Very often in previous studies the diagnosis of diabetes has been based on self-reported diabetes or fasting glucose measurement [5, 6, 8, 9], underestimating incident diabetes.”
BackgroundStatins in the primary prevention of cardiovascular disease
Reiner, Ž. (2013) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2013.80 · Cited by 189
Okamura, T., Tsukamoto, K., Arai, H., Fujioka, Y., Ishigaki, Y., Koba, S., Ohmura, H., Shoji, T., Yokote, K., Yoshida, H., et al. (2024) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.gl2022 · Cited by 302
The emerging role of HDL in glucose metabolism
Drew, B. G., Rye, K.-A., Duffy, S. J., Barter, P., & Kingwell, B. A. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.235 · Cited by 307
Mining Electronic Health Records (EHRs): A Survey
Yadav, P., Steinbach, M., Kumar, V., & Simon, G. (2018) · ACM Computing Surveys · doi:10.1145/3127881 · Cited by 299
“some found it to be beneficial [365] and some found it to be detrimental [366].”
BackgroundAssessing the Role of Circulating, Genetic, and Imaging Biomarkers in Cardiovascular Risk Prediction
Wang, T. J. (2011) · Circulation · doi:10.1161/circulationaha.109.912568 · Cited by 294
Naci, H., Brugts, J., & Ades, T. (2013) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.111.000071 · Cited by 292
Dyslipidemia in Type 2 Diabetes: Prevalence, Pathophysiology, and Management
Chehade, J. M., Gladysz, M., & Mooradian, A. D. (2013) · Drugs · doi:10.1007/s40265-013-0023-5 · Cited by 290
8. Cardiovascular Disease and Risk Management
American Diabetes Association (2015) · Diabetes Care · doi:10.2337/dc15-s011 · Cited by 233
A statin-dependent QTL for GATM expression is associated with statin-induced myopathy
Mangravite, L. M., Engelhardt, B. E., Medina, M. W., Smith, J. D., Brown, C. D., Chasman, D. I., Mecham, B. H., Howie, B., Shim, H., Naidoo, D., et al. (2013) · Nature · doi:10.1038/nature12508 · Cited by 224
Self-citation9. Cardiovascular Disease and Risk Management
American Diabetes Association (2017) · Diabetes Care · doi:10.2337/dc17-s012 · Cited by 223
Drug-Induced Hyperglycaemia and Diabetes
Fathallah, N., Slim, R., Larif, S., Hmouda, H., & Ben Salem, C. (2015) · Drug Safety · doi:10.1007/s40264-015-0339-z · Cited by 205
“In a meta-analysis of six trials, with a total of 57,593 patients, the incidence of diabetes was 13 % higher in patients receiving statin therapy than in those not receiving a statin [48].”
BackgroundTatonetti, N. P., Denny, J. C., Murphy, S. N., Fernald, G. H., Krishnan, G., Castro, V, Yue, P., Tsau, P. S., Kohane, I., Roden, D. M., et al. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.83 · Cited by 201
Chruściel, P., Sahebkar, A., Rembek-Wieliczko, M., Serban, M.-C., Ursoniu, S., Mikhailidis, D. P., Jones, S. R., Mosteoru, S., Blaha, M. J., Martin, S. S., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.07.897 · Cited by 194
Hodis, H. N., & Mack, W. J. (2022) · The Cancer Journal · doi:10.1097/ppo.0000000000000591 · Cited by 187
Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): From bench to bedside
Bao, X., Liang, Y., Chang, H., Cai, T., Feng, B., Gordon, K., Zhu, Y., Shi, H., He, Y., & Xie, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01690-3 · Cited by 187
“34 Furthermore, while an established association exists between statin therapy and the risk of T2D, 494 and certain mouse studies have suggested a requisite role of PCSK9 in maintaining pancreatic functionality, 495 no established correlation has been found between PCSK9 inhibition and insulin…”
BackgroundMancini, G. B. J., Baker, S., Bergeron, J., Fitchett, D., Frohlich, J., Genest, J., Gupta, M., Hegele, R. A., Ng, D., & Pope, J. (2011) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2011.05.007 · Cited by 188
“ASCOT, Anglo-Scandinavian Cardiac Outcomes Trial; CI, confidence int Heart Protection Study; JUPITER, Justification for the Use of Statins in Preven with Pravastatin in Ischaemic Disease; WOSCOPS, West of Scotland Corona Adapted from Rajpathak et al.(118)”
BackgroundMethodTargeting inflammation in diabetes: Newer therapeutic options
Agrawal, N. K. (2014) · World Journal of Diabetes · doi:10.4239/wjd.v5.i5.697 · Cited by 186
Dormuth, C. R., Filion, K. B., Paterson, J. M., James, M. T., Teare, G. F., Raymond, C. B., Rahme, E., Tamim, H., Lipscombe, L., & for the Canadian Network for Observational Drug Effect Studies (CNODES) Investigators (2014) · BMJ · doi:10.1136/bmj.g3244 · Cited by 180
Lonn, E., Bosch, J., Teo, K. K., Pais, P., Xavier, D., & Yusuf, S. (2010) · Circulation · doi:10.1161/circulationaha.109.873232 · Cited by 174
The diabetogenic action of statins — mechanisms and clinical implications
Betteridge, D. J., & Carmena, R. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.194 · Cited by 172
Therapeutic approaches targeting inflammation for diabetes and associated cardiovascular risk
Goldfine, A. B., & Shoelson, S. E. (2017) · Journal of Clinical Investigation · doi:10.1172/jci88884 · Cited by 172
“This was demonstrated in JUPITER, where recipients of rosuvastatin had a higher reported incidence of diabetes (44), a finding that has been born out in additional studies (47).”
Statin use and risk of new-onset diabetes: A meta-analysis of observational studies
Casula, M., Mozzanica, F., Scotti, L., Tragni, E., Pirillo, A., Corrao, G., & Catapano, A. L. (2017) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2017.03.001 · Cited by 172
“Several meta-analyses have thus evaluated data from available trials to de fi ne whether statin therapy may have a role in the development of type 2 diabetes, and observed an excess risk ranging from 9% up to 13% [10 e 14].”
Colhoun, H. M., Ginsberg, H. N., Robinson, J. G., Leiter, L. A., Müller-Wieland, D., Henry, R. R., Cariou, B., Baccara-Dinet, M. T., Pordy, R., Merlet, L., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw292 · Cited by 172
Yeganeh, B., Wiechec, E., Ande, S. R., Sharma, P., Moghadam, A. R., Post, M., Freed, D. H., Hashemi, M., Shojaei, S., Zeki, A. A., et al. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.02.007 · Cited by 169
Antioxidant Effects of Statins by Modulating Nrf2 and Nrf2/HO-1 Signaling in Different Diseases
Mansouri, A., Reiner, Ž., Ruscica, M., Tedeschi-Reiner, E., Radbakhsh, S., Bagheri Ekta, M., & Sahebkar, A. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11051313 · Cited by 162
Banach, M., Rizzo, M., Toth, P. P., Farnier, M., Davidson, M. H., Al-Rasadi, K., Aronow, W. S., Athyros, V., Djuric, D. M., Ezhov, M. V., et al. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.1039980 · Cited by 162
“(2015) 14(6) 937 in their meta-analysis [38] concluded that although high-dose statin therapy compared with moderate-dose statin therapy was associated with a higher incidence of NOD (by 12%), it was also related to significant reduction in major CV events (by 16%).”
BackgroundInfluentialChauvin, B., Drouot, S., Barrail‐Tran, A., & Taburet, A. (2013) · Clinical Pharmacokinetics · doi:10.1007/s40262-013-0075-4 · Cited by 164
“Statins may accelerate progression to diabetes mellitus via molecular mechanisms that impact insulin resistance and cellular metabolism of carbohydrates [72].”
BackgroundGalicia-Garcia, U., Jebari, S., Larrea-Sebal, A., Uribe, K. B., Siddiqi, H., Ostolaza, H., Benito-Vicente, A., & Martín, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21134725 · Cited by 149
“Interestingly, multiple meta-analyses have found that the risk of statin-associated T2DM is higher in participants taking higher doses when compared to patients taking lower doses [15,16,47].”
BackgroundReporting of conflicts of interest in meta-analyses of trials of pharmacological treatments
Roseman, M. (2011) · JAMA · doi:10.1001/jama.2011.257 · Cited by 145
“In 7 of 29 meta-analyses (Table 3), 100% of included RCTs disclosed at least 1 form of COI in the original RCT publications.(37,38,40,44,47,54,60) In 4 of these 7 meta-analyses,(37,44,54,60) 100% of included RCTs that reported study funding were funded by the pharmaceutical industry.”
BackgroundStatin use and the risk of developing diabetes: a network meta‐analysis
Thakker, D., Nair, S., Pagada, A., Jamdade, V., & Malik, A. (2016) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.4020 · Cited by 144
Understanding the molecular mechanisms of statin pleiotropic effects
German, C. A., & Liao, J. K. (2023) · Archives of Toxicology · doi:10.1007/s00204-023-03492-6 · Cited by 177
Statin use and risk of developing diabetes: results from the Diabetes Prevention Program
Crandall, J. P., Mather, K., Rajpathak, S. N., Goldberg, R. B., Watson, K., Foo, S., Ratner, R., Barrett-Connor, E., & Temprosa, M. (2017) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2017-000438 · Cited by 137
Self-citationCholesterol metabolism, pancreatic β-cell function and diabetes
Perego, C., Da Dalt, L., Pirillo, A., Galli, A., Catapano, A. L., & Norata, G. D. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2019.04.012 · Cited by 135
Differential metabolic effects of distinct statins
Koh, K. K., Sakuma, I., & Quon, M. J. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.10.036 · Cited by 130
Nielsen, S. F., & Nordestgaard, B. G. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70173-1 · Cited by 125
Statins and risk of treated incident diabetes in a primary care population
Zaharan, N. L., Williams, D., & Bennett, K. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04403.x · Cited by 123
Bardini, G., Rotella, C. M., & Giannini, S. (2012) · The Review of Diabetic Studies · doi:10.1900/rds.2012.9.82 · Cited by 137
The incidence of type 2 diabetes in the United Kingdom from 1991 to 2010
Holden, S. E., Barnett, A. H., Peters, J. R., Jenkins‐Jones, S., Poole, C. D., Morgan, C. L., & Currie, C. J. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12123 · Cited by 122
“There is some concern that statin use may increase the incidence of diabetes, but despite this uncertainty, the benefits of statins on cardiovascular disease outweigh any possible diabetes risk [29].”
BackgroundAn assessment by the Statin Diabetes Safety Task Force: 2014 update
Maki, K. C., Ridker, P. M., Brown, W. V., Grundy, S. M., & Sattar, N. (2014) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2014.02.012 · Cited by 119
Self-citationSampson, U. K., Linton, M. F., & Fazio, S. (2011) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e3283470359 · Cited by 116
Therapeutic Approaches to Target Inflammation in Type 2 Diabetes
Goldfine, A. B., Fonseca, V., & Shoelson, S. E. (2011) · Clinical Chemistry · doi:10.1373/clinchem.2010.148833 · Cited by 116
Shen, L., Shah, B. R., Reyes, E., Thomas, L. E., WOJDYLA, D. M., Diem, P., Leiter, L. A., Charbonnel, B. H., VIu, M., Horton, E. S., et al. (2013) · BMJ · doi:10.1136/bmj.f6745 · Cited by 124
Tenenbaum, A., & Fisman, E. Z. (2012) · Cardiovascular Diabetology · doi:10.1186/1475-2840-11-140 · Cited by 107
“Multiple studies showed that most popular statins - simvastatin, atorvastatin, and rosuvastatin - have deleterious effects on glycemic control [72-83].”
Background10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026
American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care · doi:10.2337/dc26-s010 · Cited by 225
Potential Benefits and Risks Associated with the Use of Statins
Khatiwada, N., & Hong, Z. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16020214 · Cited by 132
“Data from RCTs show an increased incidence of diabetes mellitus during statin therapy is due to the patients who are already at a higher risk of diabetes progressing to diabetes earlier than they would have otherwise [83,84].”
BackgroundStatins are diabetogenic – Myth or reality?
Sattar, N. A., & Taskinen, M. (2012) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2012.06.001 · Cited by 117
Chamberlain, J. J., Johnson, E. L., Leal, S., Rhinehart, A. S., Shubrook, J. H., & Peterson, L. (2018) · Annals of Internal Medicine · doi:10.7326/m18-0222 · Cited by 113
Statins and the Risk of Diabetes: Evidence From a Large Population-Based Cohort Study
Corrao, G., Ibrahim, B., Nicotra, F., Soranna, D., Merlino, L. G., Catapano, A. L., Tragni, E., Casula, M., Grassi, G. M., & Mancia, G. (2014) · Diabetes Care · doi:10.2337/dc13-2215 · Cited by 112
“Meta-analyses of clinical trials, however, showed a weaker increased risk of newonset diabetes by;10% (7,8,23).”
BackgroundRosuvastatin: Beyond the cholesterol-lowering effect
Cortese, F., Gesualdo, M., Cortese, A. M., Carbonara, S., Devito, F., Zito, A., Ricci, G., Scicchitano, P., & Ciccone, M. M. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.02.012 · Cited by 108
Toth, P. P. (2012) · Yearbook of Medicine · doi:10.1016/s0084-3873(12)00318-5 · Cited by 96
Hodis, H. N., Collins, P., Mack, W. J., & Schierbeck, L. L. (2012) · Climacteric · doi:10.3109/13697137.2012.656401 · Cited by 107
Statin induced diabetes and its clinical implications
Aiman, U., Najmi, A., & Khan, R. A. (2014) · Journal of Pharmacology and Pharmacotherapeutics · doi:10.4103/0976-500x.136097 · Cited by 105
“, found a 13% increase in diabetes risk with no heterogeneity across trials.[6] However, when data from WOSCOP was included, this risk became statistically insignificant and resulted in significant heterogeneity among component studies.”
NLA Task Force on Statin Safety - 2014 update
Jacobson, T. A. (2014) · Journal of clinical lipidology · doi:10.1016/j.jacl.2014.03.003 · Cited by 96
Coming full circle in diabetes mellitus: from complications to initiation
Harcourt, B. E., Penfold, S. A., & Forbes, J. M. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.236 · Cited by 97
Dyslipidemia in diabetes mellitus and cardiovascular disease
Warraich, H. J., & Rana, J. S. (2017) · Cardiovascular Endocrinology · doi:10.1097/xce.0000000000000120 · Cited by 103
Metabolic syndrome: nature, therapeutic solutions and options
Onat, A. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.585462 · Cited by 95
“2 Statin use and increased risk of diabetes and mortality Usage of statin drugs has been reported to increase modestly the risk of incident diabetes [91,92].”
BackgroundKlug, E., Raal, F. J., Marais, A. D., Taskinen, M.-R., Dalby, A., Schamroth, C., Rapeport, N., Jankelow, D., Blom, D. J., Catsicas, R., et al. (2012) · Journal of Endocrinology Metabolism and Diabetes of South Africa · doi:10.1080/22201009.2012.10872296 · Cited by 86
FDA drug safety communications: a narrative review and clinical considerations for older adults
Marcum, Z. A., Vande Griend, J. P., & Linnebur, S. A. (2012) · The American Journal of Geriatric Pharmacotherapy · doi:10.1016/j.amjopharm.2012.05.002 · Cited by 85
Statins: Is It Really Time to Reassess Benefits and Risks?
Goldfine, A. B. (2012) · New England Journal of Medicine · doi:10.1056/nejmp1203020 · Cited by 82
Statin use and risk of diabetes mellitus
Chogtu, B., Magazine, R., & Bairy, K. L. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i2.352 · Cited by 88
Lipid, blood pressure and kidney update 2013
Banach, M., Serban, C., Aronow, W. S., Rysz, J., Dragan, S., Lerma, E. V., Apetrii, M., & Covic, A. (2014) · International Urology and Nephrology · doi:10.1007/s11255-014-0657-6 · Cited by 73
“Changes in the LDL-C concentration do not influence the risk of NOD, but older age, higher baseline fasting glucose levels and other features of metabolic syndrome [42] are the strongest predictors of NOD [34].”
BackgroundInfluentialToth, P. P. (2012) · Yearbook of Endocrinology · doi:10.1016/j.yend.2012.05.044 · Cited by 70
Mancini, G. B. J., Hegele, R. A., & Leiter, L. A. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.10.019 · Cited by 70
Macedo, A. F., Douglas, I., Smeeth, L. L., Forbes, H. J., & Ebrahim, S. B. J. (2014) · BMC Cardiovascular Disorders · doi:10.1186/1471-2261-14-85 · Cited by 77
“Other studies have provided conflicting results regarding statin use and T2DM, including a nested case–control study using data from the UK General Practice Research Database (GPRD) that reported no strong evidence of a harmful effect of statins on the development of T2DM [11-13].”
ResultItoh, H., Komuro, I., Takeuchi, M., Akasaka, T., Daida, H., Egashira, Y., Fujita, H., Higaki, J., Hirata, K.-I., Ishibashi, S., et al. (2018) · Diabetes Care · doi:10.2337/dc17-2224 · Cited by 69
Diabetogenic Action of Statins: Mechanisms
Carmena, R., & Betteridge, D. J. (2019) · Current Atherosclerosis Reports · doi:10.1007/s11883-019-0780-z · Cited by 85
Statins for primary prevention of cardiovascular disease: the benefits outweigh the risks
Minder, C. M., Blumenthal, R. S., & Blaha, M. J. (2013) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e32836429e6 · Cited by 74
PCSK9 and diabetes: is there a link?
Momtazi‐Borojeni, A. A., Banach, M., Pirro, M., Stein, E. A., & Sahebkar, A. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.01.006 · Cited by 65
Ko, M. J., Jo, A. J., Kim, Y. J., Kang, S. H., Cho, S., Jo, S., Park, C., Yun, S., Lee, W. J., & Park, D. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.118.011320 · Cited by 69
Brunham, L. R., Kruit, J. K., Hayden, M. R., & Verchere, C. B. (2010) · Current Diabetes Reports · doi:10.1007/s11892-009-0090-x · Cited by 67
“In addition, a meta-analysis of statin trials suggests a slight increased risk of diabetes in patients receiving statins when data from WOSCOPS are excluded [37].”
BackgroundRaja-Khan, N., Kunselman, A. R., Hogeman, C. S., Stetter, C. M., Demers, L. M., & Legro, R. S. (2011) · Fertility and Sterility · doi:10.1016/j.fertnstert.2010.11.040 · Cited by 60
Statins and diabetes risk: how real is it and what are the mechanisms?
Robinson, J. G. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000172 · Cited by 58
“9–13%, with little heterogeneity between trials [3,4].”
Wang, H. J., Park, J. Y., Kwon, O., Choe, E. Y., Kim, C. H., Hur, K. Y., Lee, M., Yun, M., Soo, B., Kim, Y., et al. (2015) · Autophagy · doi:10.1080/15548627.2015.1091139 · Cited by 67
“Recent metaanalyses of major statin trials also demonstrated that the risk for T2DM is higher in statin users than in nonusers.(6,7) This effect is dose-dependent(8): the risk of developing diabetes is 12% higher in patients on intensive-dose statin therapy than those on moderate-dose therapy, and this effect is likel…”
BackgroundNew evidence on pitavastatin: efficacy and safety in clinical studies
Teramoto, T., Shimano, H., Yokote, K., & Urashima, M. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656561003641990 · Cited by 63
“The effects of statins on HbA1c levels and the onset of diabetes have been controversial [42].”
BackgroundKain, V., Kapadia, B., Misra, P., & Saxena, U. (2015) · Scientific Reports · doi:10.1038/srep13823 · Cited by 57
Lipids, blood pressure and kidney update 2015
Banach, M., Aronow, W. S., Serban, M.-C., Rysz, J., Voroneanu, L., & Covic, A. (2015) · Lipids in Health and Disease · doi:10.1186/s12944-015-0169-0 · Cited by 56
“Furthermore, estimated risk of NOD from statin treatment is approximately one in 255–498 patients over 4 years [31–33].”
BackgroundOvercoming toxicity and side-effects of lipid-lowering therapies
Wilkinson, M. J., Laffin, L. J., & Davidson, M. H. (2014) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2014.01.006 · Cited by 63
Metadata
- Authors
- Rajpathak, S. N., Kumbhani, D. J., Crandall, J., Barzilai, N., Alderman, M., & Ridker, P. M.
- Affiliations
- Albert Einstein College of Medicine (US)
- Cleveland Clinic (US)
- Brigham and Women's Hospital (US)
- Corresponding author
- Rajpathak, Swapnil N.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2009-10-01
- Volume
- 32
- Issue
- 10
- Pages
- 1924-1929
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC2752935
- OpenAlex
- W2121535401
- Cited by
- 439
- References
- 21
- Citations by year
- 2026: 5 · 2025: 5 · 2024: 20 · 2023: 15 · 2022: 19 · 2021: 19 · 2020: 16 · 2019: 34 · 2018: 21 · 2017: 28 · 2016: 27 · 2015: 45 · 2014: 41 · 2013: 50 · 2012: 44
- FWCI
- 5.00
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- Funders
- National Institute for Health and Care Research
- National Institutes of Health
- National Institute of Diabetes and Digestive and Kidney Diseases (5P60DK2054, P60DK020541)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- statin therapy, type 2 diabetes, incident diabetes risk, WOSCOPS, Heart Protection Study, ASCOT trial, JUPITER trial, CORONA trial, cardiovascular risk
- MeSH terms
- Cardiovascular Diseases, Diabetes Mellitus, Type 2, Female, Humans, Male, Risk Factors, Randomized Controlled Trials as Topic, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

